Q-omics provides the consensus-scored TH profile across patient tissues and cancer cell-line models. TH expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TH is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TH RNA expression shows 10,613 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UCEC, KIRC, and PCPG as cancer lineages where TH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TH survival associations across molecular data types. TH RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TH RNA expression–survival associations across cancer types. High TH expression shows unfavorable associations in UCEC, KIRC, DLBC, LUAD, LUSC and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for TH RNA expression.
This table summarizes TH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TH shows lower tumor expression in KIRC, KICH and LIHC and higher tumor expression in COAD, HNSC and BRCA. The KIRC box plot shows higher TH RNA expression in normal versus tumor tissue (log2 FC = −0.211, t-test p < 0.001).
This table shows molecular features associated with TH in patient tissues and cancer cell lines. In patient samples, TH shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, TH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
